Skip to main navigation

Investors and Media

Press Releases

Keyword Search

  • June 11, 2026
    Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk Myelodysplastic Syndromes
  • May 11, 2026
    Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update
  • May 4, 2026
    Kyntra Bio to Report First Quarter 2026 Financial Results
  • April 8, 2026
    Kyntra Bio to Present at the 25th Annual Needham Virtual Healthcare Conference
  • March 16, 2026
    Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
  • March 9, 2026
    Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results
  • February 23, 2026
    Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026
  • February 17, 2026
    Kyntra Bio to Participate in Upcoming Investor Conferences
  • January 7, 2026
    FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum

Investors and Media

  • Investor Overview
  • Stock Information
  • Press Releases
  • Events & Presentations
  • Corporate Governance
  • SEC Filings
  • Financial Information
  • Shareholder Services
  • Investor FAQs

Kyntra Bio, Inc.

Volume:

Minimum 15 minutes delayed. Source: LSEG

Investor and Media Contact

  • Investors:
    David DeLucia, CFA
    Chief Financial Officer
    ir@kyntrabio.com

Shareholder Tools

  • Print Page
  • RSS Feeds
  • E-mail Alerts
  • Terms of Use
  • Privacy Notice
  • About Us
  • Focus Area
  • Pipeline
  • Clinical Trials
  • Investors and Media
  • Terms of Use
  • Privacy Notice
  • © 2026 Kyntra Bio, Inc.
  • 350 Bay St, Ste 100 # 6009 San Francisco, CA 94133 USA